Phospho-SIRT1 (Ser47) Antibody

What is Phospho-SIRT1 (Ser47) Antibody and what does it detect?

Phospho-SIRT1 (Ser47) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of SIRT1 protein only when phosphorylated at Serine 47. This highly specific antibody recognizes the post-translational modification of SIRT1 at this particular residue, enabling researchers to distinguish between phosphorylated and non-phosphorylated forms of the protein. The antibody is typically generated using a synthesized peptide derived from human SIRT1 (Accession Q96EB6), corresponding to amino acid residues surrounding the phosphorylated Ser47 site .

SIRT1 (Silent Information Regulator 1) is a NAD+-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics. It coordinates several distinct cellular functions including cell cycle regulation, DNA damage response, metabolism, apoptosis, and autophagy. SIRT1 can modulate chromatin function through deacetylation of histones and promote alterations in methylation of histone and DNA, leading to transcriptional repression .

How is SIRT1 phosphorylation regulated in cellular contexts?

SIRT1 phosphorylation is regulated through complex mechanisms involving multiple kinases and cellular signaling pathways:

• Cell Cycle-Dependent Regulation: Cyclin B/Cdk1 has been identified as a major cell cycle-dependent kinase that forms a complex with and phosphorylates SIRT1. This phosphorylation is particularly relevant during mitotic phases of the cell cycle .

• Multi-site Phosphorylation: Mass spectrometry analysis has identified 13 residues in SIRT1 that are phosphorylated in vivo. These phosphorylation sites are located in either the N-terminal domain or the C-terminal domain of SIRT1, not in the conserved catalytic core domain .

• Hierarchical Phosphorylation: Evidence suggests that second-site phosphorylation may be required for efficient phosphorylation by certain kinases. Experiments have shown that dephosphorylation of SIRT1 reduces its suitability as a substrate for cyclin B/Cdk1, indicating that initial phosphorylation at some sites might prime SIRT1 for subsequent phosphorylation at other sites .

• Mitotic Kinase Involvement: A mitotic kinase mix containing multiple mitotic-phase kinases in addition to cyclin B/Cdk1 has been shown to maximally phosphorylate SIRT1, suggesting cooperative action of multiple kinases .

What methods are available for detecting phosphorylated SIRT1 in experimental samples?

Researchers have several methodological options for detecting phosphorylated SIRT1:

• Immunodetection Methods:

  • Western blotting using phospho-specific antibodies like Phospho-SIRT1 (Ser47)

  • Immunocytochemistry for cellular localization studies

  • Immunoprecipitation followed by western blotting for enhanced sensitivity

• Phosphoprotein-Specific Staining:

  • Pro-Q Diamond phosphoprotein reagent can be used to stain gels containing affinity-purified SIRT1

  • This method detects all phosphorylated residues, not just specific sites

• Phospho-specific Antibodies:

  • Antibodies that detect the phosphorylated serine residue in the consensus Cdk recognition motif (K/R-S*-P-x-K/R)

  • Site-specific antibodies like Phospho-SIRT1 (Ser47)

• Mass Spectrometry:

  • Provides comprehensive identification of all phosphorylation sites

  • Can be used to determine stoichiometry of phosphorylation at different sites

What is the subcellular localization of phosphorylated SIRT1?

Immunohistochemistry and other localization studies have revealed that both SIRT1 and Phospho-SIRT1 are predominantly localized in the nucleus. This nuclear localization is consistent with SIRT1's known functions in regulating gene expression through histone deacetylation and interaction with nuclear transcription factors .

The specific subcellular distribution pattern may vary depending on:

• Cell type

• Physiological state

• Disease condition (e.g., cancer vs. normal tissue)

• Specific phosphorylation sites being examined

In colorectal cancer tissues, both SIRT1 and Phospho-SIRT1 maintain their nuclear localization, though their expression levels are significantly elevated compared to adjacent normal tissues .

How does phosphorylation affect SIRT1 deacetylase activity?

Phosphorylation significantly modulates SIRT1's enzymatic activity, with complex effects depending on the specific residues involved:

What is the relationship between SIRT1 phosphorylation and cancer development?

The relationship between SIRT1 phosphorylation and cancer is complex and appears to be context-dependent:

• Expression Patterns in Cancer: Both SIRT1 and Phospho-SIRT1 show elevated expression in colorectal cancer tissues compared to adjacent normal tissues, suggesting potential roles in oncogenesis .

• Clinical Correlations:

  • SIRT1 expression in cancer tissues associates with patient age, TNM stage, and mutant P53 loss

  • Phospho-SIRT1 expression specifically correlates with Ki67, a marker of cellular proliferation

  • The ratio of Phospho-SIRT1 to total SIRT1 is higher in cancer tissues than normal tissues

• Dual Nature: SIRT1 appears to have dual characteristics in colorectal cancer, potentially functioning as both tumor suppressor and oncogene. Evidence suggests that phosphorylation status may be a key determinant of which role SIRT1 plays in cancer formation .

• Transcriptional vs. Post-translational Regulation: Interestingly, while protein levels of both SIRT1 and Phospho-SIRT1 are elevated in cancer tissues, SIRT1 mRNA levels show no significant difference between cancer and normal tissues. This indicates that post-translational modifications, including phosphorylation, rather than transcriptional changes, may be the primary regulatory mechanism in cancer contexts .

Table 1: Correlation of SIRT1 and Phospho-SIRT1 with Clinical Parameters in Colorectal Cancer

How do different kinases regulate SIRT1 phosphorylation throughout the cell cycle?

SIRT1 phosphorylation is dynamically regulated by multiple kinases through the cell cycle:

• Cell Cycle-Specific Kinases:

  • Cyclin D/Cdk 4,6: Active during G1 and into S phase

  • Cyclin E/Cdk 2: Active from late G1 phase into S phase

  • Cyclin A/Cdk2: Active during S phase

  • Cyclin B/Cdk1: Activated upon passing the G2/M checkpoint and inactivated upon entry into anaphase

• Cyclin B/Cdk1 as a Key Regulator:

  • Forms a complex with SIRT1

  • Directly phosphorylates SIRT1 in vitro

  • Particularly important during mitotic phases

  • Potentially targets threonine 530 and serine 540

• Cooperative Kinase Activity:

  • Experimental evidence suggests that multiple kinases work together for maximal SIRT1 phosphorylation

  • Mitotic kinase mixes containing multiple mitotic-phase kinases in addition to cyclin B/Cdk1 produce maximal phosphorylation

• Priming Phosphorylation:

  • Second-site phosphorylation appears necessary for efficient phosphorylation by certain kinases

  • Dephosphorylated SIRT1 is a poor substrate for cyclin B/Cdk1, indicating that pre-existing phosphorylation at some sites may facilitate additional phosphorylation events

What experimental approaches can be used to manipulate SIRT1 phosphorylation in research models?

Researchers can employ several strategies to manipulate SIRT1 phosphorylation:

• Site-Directed Mutagenesis:

  • Generate phospho-mimetic mutants (e.g., S→D or S→E substitutions) to simulate constitutive phosphorylation

  • Create phospho-deficient mutants (e.g., S→A substitutions) to prevent phosphorylation

  • These approaches allow assessment of the functional consequences of phosphorylation at specific sites

• Kinase Modulation:

  • Use specific kinase inhibitors (e.g., Cdk inhibitors) to prevent phosphorylation

  • Employ constitutively active kinase constructs to enhance phosphorylation

  • Apply cell cycle synchronization methods to enrich for specific phases with distinct kinase activities

• Phosphatase Treatment:

  • Lambda phosphatase (λppase) or calf intestinal phosphatase (CIP) treatment can be used to experimentally dephosphorylate SIRT1

  • Dose-dependent treatments can achieve partial dephosphorylation

• Cell-Based Systems:

  • Cell cycle synchronization to study phase-specific phosphorylation

  • Stress induction models to examine phosphorylation responses

  • Cancer cell lines vs. normal cells to study disease-specific patterns

How can phosphorylation status be integrated into mechanistic studies of SIRT1 function?

Integrating phosphorylation status into mechanistic SIRT1 studies requires sophisticated experimental approaches:

• Structure-Function Analysis:

  • Utilize protein modeling based on homology and ab initio approaches (e.g., Robetta server) to predict how phosphorylation affects protein structure

  • Examine how phosphorylation sites potentially regulate substrate access and protein interactions

• Enzymatic Activity Assays:

  • Employ fluorogenic peptide-substrate-based assay systems (e.g., Fluor-de Lys) to compare enzymatic activity of phosphorylated versus dephosphorylated SIRT1

  • Use site-specific mutations to determine the contribution of individual phosphorylation sites

• Proteomics Approaches:

  • Mass spectrometry to identify the complete phosphorylation pattern

  • Phospho-proteomics to quantify changes in phosphorylation under various conditions

  • Proximity labeling to identify interactors specific to phosphorylated SIRT1

• Temporal Analysis:

  • Time-course experiments following stimulation or stress

  • Cell cycle synchronization and release to track dynamic changes

  • Pulse-chase approaches to determine phosphorylation turnover rates

Table 2: Experimental Methods for Manipulating and Detecting SIRT1 Phosphorylation

What are the optimal conditions for using Phospho-SIRT1 (Ser47) Antibody in Western blotting?

Optimizing Western blot protocols for Phospho-SIRT1 (Ser47) detection requires attention to several technical details:

• Sample Preparation:

  • Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers

  • Process samples quickly and keep them cold to preserve phosphorylation status

  • Consider using phosphatase inhibitor cocktails specifically designed for phosphoprotein preservation

• Gel Electrophoresis:

  • SIRT1 is approximately 120 kDa; use appropriate percentage gels (typically 8-10% acrylamide)

  • Include phosphorylated protein standards as controls

  • Consider Phos-tag gels for enhanced separation of phosphorylated species

• Transfer and Blocking:

  • Standard PVDF membranes are suitable for most applications

  • Block with 5% BSA in TBST rather than milk (milk contains phosphatases that may interfere)

  • Consider enhanced chemiluminescence detection systems for optimal sensitivity

• Antibody Conditions:

  • Typical dilution: Follow manufacturer recommendations (often 1:1000)

  • Incubation: Overnight at 4°C for primary antibody

  • Include appropriate positive controls (e.g., extracts from cells with known SIRT1 phosphorylation status)

  • Consider stripping and reprobing with total SIRT1 antibody for normalization

How can I troubleshoot common issues with Phospho-SIRT1 detection?

When facing challenges in Phospho-SIRT1 detection, consider these troubleshooting approaches:

• Weak or No Signal:

  • Verify phosphorylation status is preserved (check phosphatase inhibitor effectiveness)

  • Enrich for phosphorylated proteins using phosphoprotein enrichment kits

  • Increase antibody concentration or incubation time

  • Consider immunoprecipitation before Western blotting to concentrate the target protein

• High Background:

  • Increase blocking time or BSA concentration

  • Reduce primary antibody concentration

  • Increase washing duration and number of washes

  • Try alternative blocking agents (e.g., commercial blocking buffers)

• Multiple Bands:

  • Verify antibody specificity with blocking peptides

  • Check for protein degradation during sample preparation

  • Consider that additional bands may represent differentially phosphorylated forms

  • Use phosphatase treatment as a negative control to confirm phospho-specificity

• Irreproducible Results:

  • Standardize cell culture conditions (confluency, passage number)

  • Control for cell cycle stage (phosphorylation varies throughout the cell cycle)

  • Carefully control protein loading and transfer efficiency

  • Document all experimental conditions meticulously

What are the key considerations for studying SIRT1 phosphorylation in cancer research?

Cancer researchers studying SIRT1 phosphorylation should consider these critical factors:

• Tissue Heterogeneity:

  • Cancer tissues display heterogeneous cell populations

  • Consider microdissection to isolate specific regions

  • Compare tumor tissue with paired adjacent normal tissue

• Context-Dependent Functions:

  • SIRT1 shows dual characteristics in cancer (both tumor-suppressive and oncogenic)

  • Phosphorylation status may determine which role predominates

  • Analyze multiple phosphorylation sites simultaneously when possible

• Clinical Correlations:

  • Collect comprehensive clinical data to correlate with molecular findings

  • Consider TNM stage, patient age, and other relevant clinical parameters

  • Analyze relationships with established biomarkers (e.g., Ki67, p53)

• Transcriptional vs. Post-translational Regulation:

  • Measure both mRNA and protein levels

  • Determine if altered expression is due to transcriptional or post-translational mechanisms

  • Calculate phosphorylated to total SIRT1 ratios to assess relative phosphorylation status

How can I integrate SIRT1 phosphorylation analysis with other post-translational modifications?

Comprehensive PTM analysis requires integrated experimental approaches:

What emerging technologies might enhance our understanding of SIRT1 phosphorylation?

Several cutting-edge technologies hold promise for advancing SIRT1 phosphorylation research:

• Proximity Labeling Proteomics:

  • BioID or APEX2 fusions with SIRT1 to identify phosphorylation-dependent interactors

  • TurboID for faster labeling kinetics in dynamic systems

  • Split-BioID to study condition-specific interactions

• Single-Cell Phosphoproteomics:

  • Analysis of phosphorylation heterogeneity within tissues

  • Correlation of phosphorylation patterns with cell states

  • Integration with single-cell transcriptomics

• CRISPR-Based Approaches:

  • Base editing to introduce phospho-null or phospho-mimetic mutations

  • CRISPRi/a to regulate kinases that target SIRT1

  • CRISPR screens to identify novel regulators of SIRT1 phosphorylation

• Live-Cell Imaging of Phosphorylation:

  • Phospho-specific intrabodies

  • FRET-based sensors for real-time phosphorylation monitoring

  • Optogenetic control of kinase activity to study temporal dynamics

How might SIRT1 phosphorylation be targeted therapeutically?

The therapeutic potential of targeting SIRT1 phosphorylation includes several strategies:

• Kinase Inhibitors:

  • Development of specific inhibitors targeting kinases that phosphorylate SIRT1

  • Repurposing existing CDK inhibitors to modulate SIRT1 phosphorylation

  • Combination approaches targeting multiple kinases in the SIRT1 regulatory network

• Phosphatase Activators/Inhibitors:

  • Compounds that modulate phosphatases acting on SIRT1

  • Targeted protein degradation approaches for phosphatases

  • Small molecules that alter phosphatase substrate specificity

• Allosteric Modulators:

  • Compounds that bind phosphorylated SIRT1 to enhance or inhibit activity

  • Molecules that stabilize specific phosphorylated conformations

  • Peptide mimetics that compete with phosphorylation-dependent interactions

• Combinatorial Approaches:

  • SIRT1 activators/inhibitors used alongside phosphorylation modulators

  • Integration with cell cycle inhibitors

  • Metabolism-targeting drugs that indirectly affect SIRT1 phosphorylation

Table 3: Potential Therapeutic Approaches Targeting SIRT1 Phosphorylation